Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Cancer Res Ther ; 2019 May; 15(3): 596-603
Article | IMSEAR | ID: sea-213390

ABSTRACT

Objective: The objective of this study is to evaluate the diagnostic and prognostic ability of fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy or radiotherapy only. Materials and Methods: Fifty-nine patients with HNSCC planned for radical nonsurgical treatment were randomized to receive either three-dimensional conformal radiotherapy or intensity-modulated radiation therapy. In addition to routine clinical examination and staging investigations, patients had a FDG PET-CT scan at baseline and on the first follow-up for response assessment. No evidence of clinicopathological disease for at least 6 months after the completion of treatment was considered confirmation of complete response. The presence or absence of disease during the follow-up period was used to calculate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PET-CT for the primary site and node. Results: At a median follow-up of 52.5 months, 55.6% of patients were alive and disease free. Response assessment PET-CT was done at a median of 9 weeks (range: 5–18 weeks). PET-CT assessment of the primary had sensitivity, specificity, PPV, and NPV of 81.8%, 93%, 75%, and 95.2%, respectively; the corresponding figures at the node were 44.4%, 95.6%, 66.7%, and 89.6%. The median baseline maximum standardized uptake value (SUVmax) at primary and node was 14.9 and 8.1, respectively. When PET-CT was done after 10 weeks, no false-positive or false-negative findings were seen. Patients with negative PET at the first follow-up had a significantly better progression-free and overall survival. Conclusions: Disease evaluation using PET-CT has an overall accuracy of 80%. High baseline SUVmax correlates with worse clinical outcomes. Negative PET-CT at the first follow-up is a predictor for survival.

2.
Indian J Pathol Microbiol ; 2014 Oct-Dec 57 (4): 542-548
Article in English | IMSEAR | ID: sea-156123

ABSTRACT

Introduction: Hemangioblastomas (HBs) are rare WHO grade I neoplasms of uncertain histogenesis. Most are sporadic and association with von Hippel-Lindau disease (VHL) is uncommon. Materials and Methods: Histomorphological and immunohistochemical evaluation of 24 cases of HBs was done. Results: Age range was 15-68 yrs (median: 30 yrs) with male:Female of 1.2:1 (M-13; F-11). Cerebellum was commonest location (n = 20), one each was seen in brain stem, cervical spinal cord, fourth ventricle and frontal lobe, respectively. VHL association was noted in 5 cases. Four cases were recurrent in nature of which 3 were in association with vHL. Histologically, reticular variant was the predominant subtype (n = 15), 5 were of cellular variant and 4 were mixed. Nuclear pleomorphism, nuclear cytoplasmic inclusions, cytoplasmic vacuolation were noted in the stromal cells in varying proportions. Immunohistochemical evaluation was successful in only 11 cases and of which 8 showed stromal cell positivity for alpha-inhibin. CD56 (NCAM), Nestin and synaptophysin positivity was seen in 6, 7 and 4 cases, respectively. Nestin positivity was noted in stromal cells only and no reactivity with the endothelial cells seen. S-100 protein and NSE positivity was seen in 8 and 10 cases, respectively. Glial fi brillary acidic protein (GFAP) showed two distinct patterns of immunoreactivity — scattered stromal cell positivity (n:5) and pattern of reactive astrogliosis positivity (n:10). CD44 positivity was noted in 5 cases. VEGF and EGFR positivity was seen in 5 cases each. None of the cases showed positivity for epithelial membrane antigen and no stromal cells in any of the cases showed positivity for CD34 and CD31. Conclusion: HBs can occur in throughout the neuroaxis. Cerebellum is the commonest site of occurrence for HBs and uncommonly can occur in the supratentorial compartment and spinal cord. Its association with vHL is uncommon and no histological or immunohistochemical correlation was identifi ed with the same.

3.
J Cancer Res Ther ; 2008 Jul-Sep; 4(3): 140-3
Article in English | IMSEAR | ID: sea-111397

ABSTRACT

Gangliogliomas (GG) are mixed glioneuronal tumors of the central nervous system (CNS), occurring mostly in the pediatric population, with common sites being temporal lobes and less commonly in the frontal and parietal lobes. We report a case of a 7-year-old child who presented with bilateral visual defects for 6 months. Magnetic resonance imaging (MRI) of the brain revealed an intensely enhancing mass lesion with calcification in the sellar and suprasellar region involving the optic chiasm and the left optic nerve. The mass showed almost bilaterally symmetrical diffuse spread along the optic tracts posteriorly and hypothalamus, temporal lobes, thalami and the basal ganglia. The lesion was radiologically indistinguishable from chiasmatic astrocytoma or a germ cell tumor but histopathological features were of a ganglioglioma. While a few optic apparatus gangliogliomas have been reported in the literature, such widespread diffuse involvement of the entire optico-chiasmal hypothalamic pathway is unusual.


Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/metabolism , Child , Combined Modality Therapy , Female , Ganglioglioma/metabolism , Humans , Hypothalamus/pathology , Immunohistochemistry , Magnetic Resonance Imaging , Neurosurgical Procedures , Optic Chiasm/pathology , Radiosurgery , Radiotherapy, Conformal , Visual Pathways/pathology
4.
J Cancer Res Ther ; 2006 Jul-Sep; 2(3): 136-9
Article in English | IMSEAR | ID: sea-111478

ABSTRACT

BACKGROUND: Cancer not only affects organ systems physically but can also affect the mind as a psychiatric disorder. Appropriate treatment can be clinically efficacious and cost-effective. With this background, a study was conducted in a regional cancer center to assess the prevalence of psychiatric disorder amongst cancer patients and correlate it with socio-demographic parameters. MATERIALS AND METHODS: Asymptomatic or minimally symptomatic cancer patients on active anticancer treatment, fulfilling inclusion criteria, were served psychiatric assessment questionnaire. The demographic and the medical data were obtained from subjects and their medical records. Correlation of prevalence of psychiatric disorder with socio-demographic parameters was done using the Chi-square test. RESULTS: Thirty-eight patients returned the questionnaire duly filled. Of them, 24 (63%) had some psychiatric disorder. All these 24 patients were suffering from depression--15 (63%) from major depression and 9 (37%) from minor depression. Only 6 (25%) patients had anxiety disorder. The prevalence of psychiatric disorder in patients aware of the diagnosis and prognosis was 58 and 55% respectively. This was significantly higher as compared to the patients who were not aware of their diagnosis and prognosis (P-value 0.019 and 0.05 respectively). CONCLUSION: High prevalence of psychiatric disorder, especially depression, amongst the cancer patients--particularly in those who were aware of the diagnosis and prognosis. A majority of these disorders are eminently treatable. Routine psychiatric evaluation of all cancer patients is a matter of debate that needs to be addressed in larger prospective surveys.


Subject(s)
Humans , Mental Disorders/epidemiology , Neoplasms/complications , Prevalence , Surveys and Questionnaires
5.
Article in English | IMSEAR | ID: sea-63644

ABSTRACT

Metastasis to the prostate is extremely uncommon. We report a 38-year-old man with sigmoid colon carcinoma, treated with surgery and adjuvant chemotherapy, who developed isolated metastasis to the prostate four years after initial treatment. He was treated with chemoradiation and remains disease-free three years after detection of metastasis.


Subject(s)
Adenocarcinoma/secondary , Adult , Colectomy/methods , Colonic Neoplasms/pathology , Combined Modality Therapy/methods , Humans , Male , Prostatic Neoplasms/secondary , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL